These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 31242909)

  • 21. The Tat Inhibitor Didehydro-Cortistatin A Prevents HIV-1 Reactivation from Latency.
    Mousseau G; Kessing CF; Fromentin R; Trautmann L; Chomont N; Valente ST
    mBio; 2015 Jul; 6(4):e00465. PubMed ID: 26152583
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study.
    Salomon H; Wainberg MA; Brenner B; Quan Y; Rouleau D; Coté P; LeBlanc R; Lefebvre E; Spira B; Tsoukas C; Sekaly RP; Conway B; Mayers D; Routy JP
    AIDS; 2000 Jan; 14(2):F17-23. PubMed ID: 10708278
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential impact of the HIV-1 non-nucleoside reverse transcriptase inhibitor mutations K103N and M230L on viral replication and enzyme function.
    Xu HT; Oliveira M; Quan Y; Bar-Magen T; Wainberg MA
    J Antimicrob Chemother; 2010 Nov; 65(11):2291-9. PubMed ID: 20852269
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors.
    Walter H; Schmidt B; Korn K; Vandamme AM; Harrer T; Uberla K
    J Clin Virol; 1999 Jun; 13(1-2):71-80. PubMed ID: 10405894
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure-activity relationship studies on clinically relevant HIV-1 NNRTIs.
    Rawal RK; Murugesan V; Katti SB
    Curr Med Chem; 2012; 19(31):5364-80. PubMed ID: 22998569
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selective cell death in HIV-1-infected cells by DDX3 inhibitors leads to depletion of the inducible reservoir.
    Rao S; Lungu C; Crespo R; Steijaert TH; Gorska A; Palstra RJ; Prins HAB; van Ijcken W; Mueller YM; van Kampen JJA; Verbon A; Katsikis PD; Boucher CAB; Rokx C; Gruters RA; Mahmoudi T
    Nat Commun; 2021 Apr; 12(1):2475. PubMed ID: 33931637
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The prevalence of resistance-associated mutations to protease and reverse transcriptase inhibitors in treatment-naïve (HIV1)-infected individuals in Casablanca, Morocco.
    Bakhouch K; Oulad-Lahcen A; Bensghir R; Blaghen M; Elfilali KM; Ezzikouri S; Abidi O; Hassar M; Wakrim L
    J Infect Dev Ctries; 2009 Jun; 3(5):380-91. PubMed ID: 19759509
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ultrasensitive HIV-1 p24 Assay Detects Single Infected Cells and Differences in Reservoir Induction by Latency Reversal Agents.
    Passaes CPB; Bruel T; Decalf J; David A; Angin M; Monceaux V; Muller-Trutwin M; Noel N; Bourdic K; Lambotte O; Albert ML; Duffy D; Schwartz O; Sáez-Cirión A
    J Virol; 2017 Mar; 91(6):. PubMed ID: 28077644
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development and significance of resistance to protease inhibitors in HIV-1-infected adults under triple-drug therapy in clinical practice.
    Romano L; Venturi G; Giomi S; Pippi L; Valensin PE; Zazzi M
    J Med Virol; 2002 Feb; 66(2):143-50. PubMed ID: 11782921
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.
    Ambrose Z; Boltz V; Palmer S; Coffin JM; Hughes SH; Kewalramani VN
    J Virol; 2004 Dec; 78(24):13553-61. PubMed ID: 15564466
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection.
    Tsai P; Wu G; Baker CE; Thayer WO; Spagnuolo RA; Sanchez R; Barrett S; Howell B; Margolis D; Hazuda DJ; Archin NM; Garcia JV
    Retrovirology; 2016 May; 13(1):36. PubMed ID: 27206407
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Temporal characterization of drug resistance associated mutations in HIV-1 protease and reverse transcriptase in patients failing antiretroviral therapy.
    Santoro MM; Svicher V; Gori C; Zaccarelli M; Tozzi V; Forbici F; D'Arrigo R; Trotta MP; Bellocchi MC; Visco-Comandini U; Cenci A; Bertoli A; Narciso P; Antinori A; Perno CF; Ceccherini-Silberstein F
    New Microbiol; 2006 Apr; 29(2):89-100. PubMed ID: 16841549
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation.
    Shan L; Deng K; Shroff NS; Durand CM; Rabi SA; Yang HC; Zhang H; Margolick JB; Blankson JN; Siliciano RF
    Immunity; 2012 Mar; 36(3):491-501. PubMed ID: 22406268
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In Vitro Reactivation of Replication-Competent and Infectious HIV-1 by Histone Deacetylase Inhibitors.
    Banga R; Procopio FA; Cavassini M; Perreau M
    J Virol; 2016 Feb; 90(4):1858-71. PubMed ID: 26656693
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
    Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
    Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD008270. PubMed ID: 23740608
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Resistance to the most recent protease and non-nucleoside reverse transcriptase inhibitors across HIV-1 non-B subtypes.
    Anta L; Blanco JL; Llibre JM; García F; Pérez-Elías MJ; Aguilera A; Pérez-Romero P; Caballero E; Vidal C; Cañizares A; Gutiérrez F; Dalmau D; Iribarren JA; Soriano V; de Mendoza C;
    J Antimicrob Chemother; 2013 Sep; 68(9):1994-2002. PubMed ID: 23629015
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emerging mutations and associated factors in patients displaying treatment failure on an etravirine-containing regimen.
    Marcelin AG; Descamps D; Tamalet C; Cottalorda J; Izopet J; Delaugerre C; Morand-Joubert L; Trabaud MA; Bettinger D; Rogez S; Ruffault A; Henquell C; Signori-Schmuck A; Bouvier-Alias M; Vallet S; Masquelier B; Flandre P; Calvez V;
    Antivir Ther; 2012; 17(1):119-23. PubMed ID: 22267476
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CARD8 is an inflammasome sensor for HIV-1 protease activity.
    Wang Q; Gao H; Clark KM; Mugisha CS; Davis K; Tang JP; Harlan GH; DeSelm CJ; Presti RM; Kutluay SB; Shan L
    Science; 2021 Mar; 371(6535):. PubMed ID: 33542150
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
    Bacheler L; Jeffrey S; Hanna G; D'Aquila R; Wallace L; Logue K; Cordova B; Hertogs K; Larder B; Buckery R; Baker D; Gallagher K; Scarnati H; Tritch R; Rizzo C
    J Virol; 2001 Jun; 75(11):4999-5008. PubMed ID: 11333879
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.
    Bunupuradah T; Ananworanich J; Chetchotisakd P; Kantipong P; Jirajariyavej S; Sirivichayakul S; Munsakul W; Prasithsirikul W; Sungkanuparph S; Bowonwattanuwong C; Klinbuayaem V; Petoumenos K; Hirschel B; Bhakeecheep S; Ruxrungtham K
    Antivir Ther; 2011; 16(7):1113-21. PubMed ID: 22024527
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.